文献速递遗传性与小管间质肾病慢性肾脏病

3岁尿筛查对Alport综合征诊断与治疗时机的影响

Impact of Age-3 Urine Screening on Diagnosis and Treatment Timing in Alport Syndrome.
PubMed 文献 · Kidney Int Rep · 2025-09-23

本研究纳入2015年8月至2024年5月在本院基因诊断的≤18岁Alport综合征患者356例,评估首次发现尿异常的场合。3岁尿筛查是最常见的首次发现场合(113例,31.7%),且其中60.2%在筛查时已符合RAS-I治疗标准。3岁尿筛查可能有助于延迟ESKD进展。

要点

  • 3岁尿筛查是Alport综合征首次发现尿异常的最常见场合,占31.7%。
  • 通过3岁尿筛查发现的Alport综合征患者中,60.2%已符合RAS-I治疗标准。
  • 3岁尿筛查可能为Alport综合征患者延迟ESKD进展提供最佳时机。

核心结论

  • 约30%的Alport综合征患者可通过3岁尿筛查获得诊断机会,其中超过半数已符合RAS-I治疗标准。
  • 3岁尿筛查可能是延迟Alport综合征患者进展至ESKD的最佳方法。

研究设计与样本

  • 回顾性研究,纳入2015年8月至2024年5月在本院基因诊断为Alport综合征且年龄≤18岁的患者356例。
  • 评估临床和遗传特征,并确定首次发现尿异常的场合,重点关注3岁尿筛查的作用。

主要发现

  • 首次发现尿异常最常见的场合是3岁尿筛查(n=113,31.7%)。
  • 遗传方式构成:X连锁女性43.3%,X连锁男性30.1%,常染色体显性19.5%,常染色体隐性6.2%。
  • 通过3岁尿筛查发现的患者中,60.2%在筛查时已符合RAS-I治疗标准。

关键数值与推荐

  • 3岁尿筛查发现尿异常者占31.7%(113/356)。
  • 3岁尿筛查发现的患者中60.2%已符合RAS-I治疗标准。

临床怎么用

  • 对3岁儿童进行公共尿筛查可能有助于早期识别Alport综合征。
  • 通过3岁尿筛查发现的Alport综合征患者中,超过半数已具备启动RAS-I治疗的指征,应及早评估并启动治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Alport syndrome is an inherited kidney disease that leads to end-stage kidney disease (ESKD) due to pathogenic variants in COL4A3/4/5, which encode type IV collagen. Promptly identifying patients with Alport syndrome and starting treatment with a renin-angiotensin system inhibitor (RAS-I) is important for delaying progression to ESKD. In Japan, public urine screening is available for all children aged 3 years. METHODS: Patients genetically diagnosed with Alport syndrome at our department between August 2015 and May 2024, who were aged ≤ 18 years, were included in the study. We evaluated their clinical and genetic characteristics and identified the circumstances under which abnormal urine findings were first detected, with a focus on the role of urine screening at the age of 3 years (age-3 urine screening). RESULTS: A total of 356 patients with Alport syndrome were eligible for this study. The most common setting for detecting urine abnormalities for the first time was during age-3 urine screening (n = 113, 31.7%). The inherited forms were as follows: X-linked (XL) female (43.3%), XL male (30.1%), autosomal dominant (AD) (19.5%), and autosomal recessive (AR) (6.2%) Alport syndrome. In addition, 60.2% of these patients already met the criteria for RAS-I treatment at the time of urine screening. DISCUSSION: Our study showed that approximately 30% of patients with Alport syndrome had the opportunity to be diagnosed through age-3 urine screening, and among them, more than half were already eligible for RAS-I treatment. Urine screening may be an optimal method for contributing to a delay in the progression to ESKD in patients with Alport syndrome.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Kitakado H, Ishimori S, Aoyama S, et al. Impact of Age-3 Urine Screening on Diagnosis and Treatment Timing in Alport Syndrome. Kidney Int Rep. 2025. PMID: 41426028. doi:10.1016/j.ekir.2025.09.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。